CLINICAL_TRIALS
trial_result
· 2019-02-06
Clinical Trial Update: Eribulin in HER2 Negative Metastatic BrCa [Phase 2]
Summary
Phase 2 trial update evaluating eribulin for HER2-negative metastatic breast cancer; results have been posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Dana-Farber Cancer Institute | Conditions: Breast Cancer | Phase 2 | Status: COMPLETED | Results posted: 2019-02-06